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Saving Lives by Reducing Harm: 
HIV Prevention and Treatment for Injecting Drug Users 
 
 
Worldwide, 10 percent of HIV infections are now due to injecting drug use.  Outside 
Africa, the number rises to nearly one in three.1  
 
Despite great efforts, the world’s supply of illicit drugs is not decreasing.  Worldwide 
opium production has doubled since the mid-1980s.2  In 2005, Afghanistan alone 
produced nearly 500 metric tons of heroin.3   Campaigns to curb drug use have included 
extra-judicial killings of drug users in Thailand, public executions of drug dealers in 
Chinese stadiums, and mass incarceration of drug users in prisons where they are 
exposed to HIV.4, ,5 6  Yet these harsh measures have done little to stem the demand for 
drugs.   
 
UNAIDS estimates that there are now 13 million injecting drug users (IDUs) 
worldwide.7  Where drug treatment is available at all, it is often ineffective or punitive.  
In Russia, with an estimated two million IDUs, “treatment” is often restricted to 
medically managed withdrawal at great expense to the patient.8  Prescription medication 
to reduce cravings for illegal opiates (substitution treatment) is illegal.9  Across Asia, 
many drug users are confined to centers that are more like prisons than health care 
facilities, and that offer little or no psychosocial or medical support.10   
 
In the absence of effective measures to reduce drug consumption and unsafe injection, 
HIV is spreading rapidly among IDUs.  Shared injection equipment is the cause of over 
80 percent of all HIV cases in Eastern Europe and Central Asia.11
 
Harm reduction programs help those unable or unwilling to abstain from drug use to 
make positive changes to protect their health and the health of others.  The following 
interventions work to prevent HIV and other harms related to injection drug use: 
 
Syringe exchange programs provide IDUs with sterile injecting equipment and remove 
contaminated injection equipment from circulation.  Syringe exchanges dramatically 
reduce the risk of HIV and hepatitis B and C: in New York City, the introduction of 
syringe exchange was followed by a 75 percent decrease in the number of HIV 
infections.12,13  Syringe exchange does not increase drug use.14  Instead, many syringe 
exchange programs act as a gateway to other services, including HIV testing, sexual 
health services, and drug treatment.15  Yet internationally, UNAIDS estimates that at best 
only 5 percent of IDUs are reached by HIV prevention services.16   
 
Opiate substitution treatment is the best researched and most effective form of 
treatment for opiate dependence, and is proven to prevent HIV among IDUs: one study 
showed that only 3.5 percent of methadone patients became infected with HIV, 
compared to 22 percent of IDUs who were not in treatment.17,18  By using methadone or 
buprenorphine to prevent withdrawal and reduce craving, substitution treatment allows 
opiate users to reduce or stop injection, stabilize their lives, and protect their health and 
that of others.  Substitution treatment is also an important tool in improving adherence to 
HIV treatment.19  The World Health Organization has added methadone and 
buprenorphine to its list of essential medicines, but both remain unavailable or illegal in 
many countries.  
 
Antiretroviral treatment (ARV) for HIV-positive IDUs not only improves the health of 
individual patients, but increases voluntary HIV testing and the effectiveness of HIV 
prevention measures.20  WHO protocols emphasize that everyone who needs ARV 
should receive it regardless of whether they use drugs.21  ARV is as effective for IDUs as 
for other patients when accompanied by basic support, though medical personnel often 
deny ARV to IDUs because of prejudice or mistaken beliefs about drug users’ ability to 
benefit from treatment.22, ,23 24   
 
Sexual health services for IDUs enable drug users to protect themselves and their 
sexual partners from HIV, preventing the sexual transmission of epidemics initially 
concentrated among IDUs.  UNAIDS urges that sexual health services be made available 
to all drug users and their partners.25
  
Human rights protections and policy reform prevent the abusive treatment, 
confidentiality violations, incarceration, harassment, and discrimination that deter drug 
users from accessing life-saving services.  The HIV/AIDS task force of the UN 
Millennium Project has recognized that repressive drug laws catalyze the HIV epidemic 
by imprisoning hundreds of thousands of drug users in prisons or forced rehabilitation 
centers where injection drug use and sex continue, yet effective drug treatment, HIV 
prevention measures, and HIV treatment are often unavailable.26   
 
Peer support and community mobilization strengthen drug programs and policies by 
empowering current and former IDUs to become their own best advocates.  Involvement 
of drug users in program design and implementation has been demonstrated to improve 
program effectiveness and coverage.27, ,28 29
 
A Five-Point Harm Reduction Approach 
to HIV Prevention and Treatment for Injecting Drug Users 
 
1. Make opiate substitution and effective drug-free treatment widely available  
2. Scale up syringe exchange  
3. Reform drug laws to end the mass incarceration of drug users  
4. Provide ARV for all drug users who need it 
5. Address the sexual health needs of drug users 
 
For more information, please visit the website of the International Harm Reduction 
Development Program of the Open Society Institute: www.soros.org/harm-reduction
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